Elucidating the precise pharmacological mechanism of action (MOA) of Normally happening compounds may be hard. Although Tarselli et al. (60) formulated the 1st de novo synthetic pathway to conolidine and showcased this Obviously developing compound successfully suppresses responses to both chemically induced and inflammation-derived pain, the pharm